Literature DB >> 18400797

Respiratory viruses other than influenza virus: impact and therapeutic advances.

W Garrett Nichols1, Angela J Peck Campbell, Michael Boeckh.   

Abstract

Though several antivirals have been developed and marketed to treat influenza virus infections, the development of antiviral agents with clinical activity against other respiratory viruses has been more problematic. Here we review the epidemiology of respiratory viral infections in immunocompetent and immunocompromised hosts, examine the evidence surrounding the currently available antivirals for respiratory viral infections other than influenza, highlight those that are in the pipeline, and discuss the hurdles for development of such agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18400797      PMCID： PMC2292575          DOI： 10.1128/CMR.00045-07

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN： 0893-8512            Impact factor:   26.132


  234 in total

1.  Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone.

Authors:  Jeremy John Wright; Gerry O'driscoll
Journal:  J Heart Lung Transplant       Date:  2005-03       Impact factor: 10.247

2.  Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.

Authors:  F Legrand; D Berrebi; N Houhou; F Freymuth; A Faye; M Duval; J F Mougenot; M Peuchmaur; E Vilmer
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

3.  Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness.

Authors:  Ann R Falsey; Mary C Criddle; Edward E Walsh
Journal:  J Clin Virol       Date:  2006-01       Impact factor: 3.168

4.  Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial.

Authors:  K L Meert; A P Sarnaik; M J Gelmini; M W Lieh-Lai
Journal:  Crit Care Med       Date:  1994-04       Impact factor: 7.598

5.  Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.

Authors:  Anjeanette Roberts; William D Thomas; Jeannette Guarner; Elaine W Lamirande; Gregory J Babcock; Thomas C Greenough; Leatrice Vogel; Norman Hayes; John L Sullivan; Sherif Zaki; Kanta Subbarao; Donna M Ambrosino
Journal:  J Infect Dis       Date:  2006-01-27       Impact factor: 5.226

6.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors:  Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal:  Nat Med       Date:  2005-08-21       Impact factor: 53.440

7.  SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.

Authors:  I-Chueh Huang; Berend Jan Bosch; Fang Li; Wenhui Li; Kyoung Hoa Lee; Sorina Ghiran; Natalya Vasilieva; Terence S Dermody; Stephen C Harrison; Philip R Dormitzer; Michael Farzan; Peter J M Rottier; Hyeryun Choe
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

8.  Croup is associated with the novel coronavirus NL63.

Authors:  Lia van der Hoek; Klaus Sure; Gabriele Ihorst; Alexander Stang; Krzysztof Pyrc; Maarten F Jebbink; Gudula Petersen; Johannes Forster; Ben Berkhout; Klaus Uberla
Journal:  PLoS Med       Date:  2005-08-23       Impact factor: 11.069

9.  Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.

Authors:  Els Keyaerts; Leen Vijgen; Christophe Pannecouque; Els Van Damme; Willy Peumans; Herman Egberink; Jan Balzarini; Marc Van Ranst
Journal:  Antiviral Res       Date:  2007-03-30       Impact factor: 5.970

10.  Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.

Authors:  Frederick G Hayden; Darrell T Herrington; Teresa L Coats; Kenneth Kim; Ellen C Cooper; Stephen A Villano; Siyu Liu; Spencer Hudson; Daniel C Pevear; Marc Collett; Mark McKinlay
Journal:  Clin Infect Dis       Date:  2003-06-06       Impact factor: 9.079
View more
  61 in total

1.  Novel Polyanions Inhibiting Replication of Influenza Viruses.

Authors:  Justyna Ciejka; Aleksandra Milewska; Magdalena Wytrwal; Jacek Wojarski; Anna Golda; Marek Ochman; Maria Nowakowska; Krzysztof Szczubialka; Krzysztof Pyrc
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 2.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

3.  Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores.

Authors:  So-Youn Park; Seunghee Baek; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Heungsup Sung; Mi-Na Kim; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Sung-Han Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

4.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

5.  The role of human metapneumovirus in the critically ill adult patient.

Authors:  Jennifer Hasvold; Michael Sjoding; Kyle Pohl; Colin Cooke; Robert C Hyzy
Journal:  J Crit Care       Date:  2015-10-23       Impact factor: 3.425

6.  Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections.

Authors:  S Nickbakhsh; F Thorburn; B VON Wissmann; J McMENAMIN; R N Gunson; P R Murcia
Journal:  Epidemiol Infect       Date:  2016-03-02       Impact factor: 2.451

7.  [Fever, coughing and dyspnea in a 38-year-old female kidney transplant recipient].

Authors:  M Porsche; E Künzli; M Dickenmann; H H Hirsch; M Battegay; N Khanna
Journal:  Internist (Berl)       Date:  2012-12       Impact factor: 0.743

8.  N-terminally truncated C protein, CNDelta25, of human parainfluenza virus type 3 is a potent inhibitor of viral replication.

Authors:  Hongxia Mao; Santanu Chattopadhyay; Amiya K Banerjee
Journal:  Virology       Date:  2009-09-10       Impact factor: 3.616

9.  Respiratory virus shedding in exhaled breath and efficacy of face masks.

Authors:  Nancy H L Leung; Daniel K W Chu; Eunice Y C Shiu; Kwok-Hung Chan; James J McDevitt; Benien J P Hau; Hui-Ling Yen; Yuguo Li; Dennis K M Ip; J S Malik Peiris; Wing-Hong Seto; Gabriel M Leung; Donald K Milton; Benjamin J Cowling
Journal:  Nat Med       Date:  2020-04-03       Impact factor: 53.440

Review 10.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.